Tuberculosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 14: | Line 14: | ||
* The number of drugs in it should be ideally not more than 3-5 drug each from a different class | * The number of drugs in it should be ideally not more than 3-5 drug each from a different class | ||
* It should have minimum side effect profile so that we could have minimum monitoring | * It should have minimum side effect profile so that we could have minimum monitoring | ||
* It should be effective against MDR, XDR and XXDR strains | * It should be effective against [[MDR]], [[XDR]] and [[XXDR]] strains | ||
* It should be administered per orally | * It should be administered per orally | ||
* It should have minimum interaction with anti retroviral drugs. | * It should have minimum interaction with anti retroviral drugs. | ||
| Line 28: | Line 28: | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Class}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Class}} | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Moxifloxacin | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[Moxifloxacin]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase III | | style="padding: 5px 5px; background: #F5F5F5;" |Phase III | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Fluoroquinolone | | style="padding: 5px 5px; background: #F5F5F5;" |[[Fluoroquinolone]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Linezolid | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Linezolid]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | | style="padding: 5px 5px; background: #F5F5F5;" |Phase II | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Oxazolidinone | | style="padding: 5px 5px; background: #F5F5F5;" |[[Oxazolidinone]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |AZD-5847 | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |AZD-5847 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | | style="padding: 5px 5px; background: #F5F5F5;" |Phase II | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Oxazolidinone | | style="padding: 5px 5px; background: #F5F5F5;" |[[Oxazolidinone]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Sutezolid | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Sutezolid]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | | style="padding: 5px 5px; background: #F5F5F5;" |Phase II | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Oxazolidinone | | style="padding: 5px 5px; background: #F5F5F5;" |[[Oxazolidinone]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Clofazimine | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Clofazimine]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | | style="padding: 5px 5px; background: #F5F5F5;" |Phase II | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Riminophenazine | | style="padding: 5px 5px; background: #F5F5F5;" |[[Riminophenazine]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |SQ-109 | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |SQ-109 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase II | | style="padding: 5px 5px; background: #F5F5F5;" |Phase II | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ethylenediamine | | style="padding: 5px 5px; background: #F5F5F5;" |[[Ethylenediamine]] | ||
|- | |- | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |PA-824 | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |PA-824 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase IIb | | style="padding: 5px 5px; background: #F5F5F5;" |Phase IIb | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Nitroimidazole | | style="padding: 5px 5px; background: #F5F5F5;" |[[Nitroimidazole]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Delamanid | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Delamanid]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase III | | style="padding: 5px 5px; background: #F5F5F5;" |Phase III | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Nitroimidazole | | style="padding: 5px 5px; background: #F5F5F5;" |[[Nitroimidazole]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Bedaquiline | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Bedaquiline]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Phase III | | style="padding: 5px 5px; background: #F5F5F5;" |Phase III | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Diarylquinoline | | style="padding: 5px 5px; background: #F5F5F5;" |[[Diarylquinoline]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" colspan="3"|Data provided by WHO<ref name=CDC>{{cite web | title = Tuberculosis (TB) Future drugs| url = http://www.who.int/bulletin/volumes/92/1/BLT-13-122028-table-T1.html }}</ref> | | style="padding: 5px 5px; background: #F5F5F5;" colspan="3"|Data provided by WHO<ref name=CDC>{{cite web | title = Tuberculosis (TB) Future drugs| url = http://www.who.int/bulletin/volumes/92/1/BLT-13-122028-table-T1.html }}</ref> | ||
Revision as of 18:50, 25 September 2014
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberculosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Tuberculosis future or investigational therapies |
|
Tuberculosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Tuberculosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Since new drug resistant tuberculosis have been emerging, the role of future therapies is vital in curbing outbreaks. The new drugs should be more effective than the current regimen and a few drugs in clinical trials have been showing good results.
Future investigations
Principles of future investigations
Any future regimen should satisfy the following principles. [1]
- It should not have more than a maximum duration of 6 months
- The dosing schedule must be simple
- The number of drugs in it should be ideally not more than 3-5 drug each from a different class
- It should have minimum side effect profile so that we could have minimum monitoring
- It should be effective against MDR, XDR and XXDR strains
- It should be administered per orally
- It should have minimum interaction with anti retroviral drugs.
- It should have atleast one new class of drug
New drugs involved in clinical trial for treatment of tuberculosis
| Drug | Phase | Class |
|---|---|---|
| Moxifloxacin | Phase III | Fluoroquinolone |
| Linezolid | Phase II | Oxazolidinone |
| AZD-5847 | Phase II | Oxazolidinone |
| Sutezolid | Phase II | Oxazolidinone |
| Clofazimine | Phase II | Riminophenazine |
| SQ-109 | Phase II | Ethylenediamine |
| PA-824 | Phase IIb | Nitroimidazole |
| Delamanid | Phase III | Nitroimidazole |
| Bedaquiline | Phase III | Diarylquinoline |
| Data provided by WHO[2] | ||